What is the current stock price of Jupiter Neurosciences, Inc. (JUNS)?

As of the latest market data, Jupiter Neurosciences, Inc. (JUNS) is trading at $0.40. The stock has seen a gain of 4.04% today.

Does Jupiter Neurosciences, Inc. (JUNS) pay a dividend?

Based on current data, Jupiter Neurosciences, Inc. does not have a confirmed active dividend policy.

What is the market cap of Jupiter Neurosciences, Inc.?

The current market capitalization of Jupiter Neurosciences, Inc. (JUNS) is approximately unavailable.

JUNS

Jupiter Neurosciences, Inc.·Healthcare

0.40

4.044%(+0.02)

Market Closed

0.45

12.839%(+0.05)

After Hours

Last Updated: — ET

52W L: $0.3152W H: $3.33

JUNS NEWS

globenewswire.com

Feb 25

Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago

JUPITER, FL, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, announces that members of senior management have been invited, as the only company this evening, to present its progress at a private investor dinner taking place Wednesday, February 25, 2026 at 6:00 PM ET at The Mar-a-Lago Club in Palm Beach, Florida.

globenewswire.com

Feb 23

Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution

Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company focused on neuroinflammation and central nervous system disorders, today announced that it has entered into an Omnibus Amendment with YA II PN, Ltd. modifying the installment payment provisions of its previously disclosed Convertible Promissory Notes issued under the Company's Standby Equity Purchase Agreement.

globenewswire.com

Jan 28

Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users

Nugevia ™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss

accessnewswire.com

Jan 27

Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference

JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026. Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.

Company Profile

Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform product primarily for the treatment of neuro-inflammation. It is developing JNS101 that is in Phase II trials for the treatment of Friedreich's Ataxia, a rare disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS102, which is in Phase II trials for the treatment of mucopolysaccharidosis Type I. The company is also developing JNS107 that is in Phase II trials for the treatment of MELAS Syndrome; and JNS108, which is in Phase II trials for the treatment of mild cognitive impairment/early Alzheimer's disease. In addition, it is developing JNS109 for amyotrophic lateral sclerosis; JNS110 for traumatic brain injury/concussion; and JNS120 for covid-19 treatment. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. The company was founded in 2016 and is headquartered in Jupiter, Florida.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2022-01-18

Beta

2.78

Websitewww.jupiterorphan.com↗